When I first got up this morning something that had previously been stated came up like it was new news, namely that the MM Trials would be the priority with additional trials for psoriasis deferred.

This makes complete sense to me, as the company intends to market the psoriasis cream as a cosmetic, without additional trials being required. The problem, as I see it, is that none of the articles discussing this, or literature from the company, clearly enunciate this strategy.

I believe that once it's clear the psoriasis cream will be on the market anywhere in the world, the stock price will soar.

Gary